15 / 74 · 0:50 · Original AXON film
PE-22-28
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
PE-22-28 | TREK-1 research
PE-22-28 comes from research on shortened versions of spadin. Its story begins with an ion channel called TREK-one. [1]
CHANNEL ASSAYS + MICE
Scientists tested how these peptides affected channel activity, stability and behaviour in mice. Those experiments explored a possible route for antidepressant drug development. [1] [2]
Human translation remains unproven
A change in a mouse behavioural test is not proof that a person’s depression will improve. It also cannot establish human brain exposure, long-term safety or comparative effectiveness. [1]
PRECLINICAL | No treatment recommendation
Use the phrase experimental candidate, and keep the evidence level visible. The research provides a hypothesis to test, not a replacement for established mental-health care. [1] [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity →Primary channel assays and mouse behavioral research
- Spadin, a sortilin-derived peptide targeting rodent TREK-1 channels →Primary mouse and cellular research on parent spadin
